Your browser version may not work well with NCBI's Web applications. More information here...
1: Science. 2007 Dec 21;318(5858):1920-3. Epub 2007 Dec 6.
Related Articles, Links
Click here to read Click here to read Click here to read
Comment in:
Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin.

Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard C, Brambrink T, Wu LC, Townes TM, Jaenisch R.

Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.

It has recently been demonstrated that mouse and human fibroblasts can be reprogrammed into an embryonic stem cell-like state by introducing combinations of four transcription factors. However, the therapeutic potential of such induced pluripotent stem (iPS) cells remained undefined. By using a humanized sickle cell anemia mouse model, we show that mice can be rescued after transplantation with hematopoietic progenitors obtained in vitro from autologous iPS cells. This was achieved after correction of the human sickle hemoglobin allele by gene-specific targeting. Our results provide proof of principle for using transcription factor-induced reprogramming combined with gene and cell therapy for disease treatment in mice. The problems associated with using retroviruses and oncogenes for reprogramming need to be resolved before iPS cells can be considered for human therapy.

Publication Types:
PMID: 18063756 [PubMed - indexed for MEDLINE]